🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

406 results for “Institut” Clear

  1. SARCLISA 20mg/mL concentrate for solution for infusion., CellProtect

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  2. SODIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Colon cancer

    phase 2 small molecule active

    1 trial

  3. SYNTOCINON 40 i.e./ml pršilo za nos, raztopina, Oxytocin Placebo

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

  4. Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Untreated small triple negative breast cancer

    phase 2 other active

    1 trial

  5. Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Recessive dystrophic epidermolysis bullosa (RDEB)

    phase 2 small molecule active

    1 trial

  6. Sodium Chloride Injection/ DEMO 0,9% w/v, EMAPALUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    SEPSIS

    phase 2 small molecule active

    1 trial

  7. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  8. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  9. Sustanon 250, solution injectable

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Androgen deficiency, palliative care

    phase 2 small molecule active

    1 trial

  10. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  11. TEMOZOLOMIDE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Diffuse low-grade gliomas

    phase 2 small molecule active

    1 trial

  12. TEMOZOLOMIDE VIATRIS 5 mg, gélule, Capivasertib, TEMOZOLOMIDE VIATRIS 100 mg, gélule, VINORELBINE ACCORD 20 mg, capsule molle, Votubia 3 mg dispersible tablets, Bavencio 20 mg/mL concentrate for solution for infusion, Peposertib, INC280, Enasidenib Mesilate, Futibatinib, TEMOZOLOMIDE VIATRIS 20 mg, gélule, Capivasertib, VINORELBINE ACCORD 30 mg, capsule molle, INC280, Enasidenib Mesilate, Votubia 5 mg dispersible tablets, Votubia 2 mg dispersible tablets, Capivasertib

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    pediatric cancer

    phase 2 small molecule active

    1 trial

  13. THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    haematological malignancies

    phase 2 small molecule active

    1 trial

  14. TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  15. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, VINCRISTINE HOSPIRA 2 mg/2 ml, solution injectable, Etoposide 20 mg/ml concentrate for solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, MELPHALAN TILLOMED 50 mg/10 mL, poudre et solvant pour solution injectable / pour perfusion, Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Ocular conservative treatment for retinoblastoma

    phase 2 small molecule active

    1 trial

  16. TRASTUZUMAB EMTANSINE, Herceptin 150 mg powder for concentrate for solution for infusion, 89Zr-Trastuzumab_IJB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  17. TREMELIMUMAB, DURVALUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    MSS and MSI colorectal and endometrial tumors

    phase 2 small molecule active

    1 trial

  18. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  19. Tarlatamab, Tarlatamab

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)

    phase 2 small molecule active

    1 trial

  20. Tecentriq 1 200 mg concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced cervical cancer

    phase 2 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.

    phase 2 small molecule active

    1 trial

  22. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  23. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  24. Temozolomide Accord 5 mg hard capsules., Temozolomide ratiopharm 20 mg, capsules, hard, Temozolomide ratiopharm 250 mg, capsules, hard, Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 180 mg hard capsules, Temozolomide Accord 140 mg hard capsules., TEMOZOLOMIDE VIATRIS 180 mg, gélule, Temozolomide ratiopharm 180 mg, capsules, hard, Temozolomide SUN 5 mg hard capsules, TEMOZOLOMIDE VIATRIS 140 mg, gélule, Temozolomide Accord 20 mg hard capsules, Temozolomide Accord 180 mg hard capsules., S95032/AG-88

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    IDH1-mutant Glioma, IDH2-mutant Glioma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources